Nuwellis Earnings Call: Margin Gains Amid Cash Strain

Nuwellis, Inc. ((NUWE)) has held its Q4 earnings call. Read on for the main highlights of the call.

Nuwellis’ latest earnings call painted a cautiously balanced picture for investors. Management emphasized signs of operational progress, including better gross margins, stronger console sales, and a sharpened strategic focus, yet the discussion was tempered by ongoing revenue pressure, heavy losses, and tight liquidity that underscore execution and funding risks in the near term.

Fourth-quarter revenue growth amid a tough backdrop

Nuwellis reported Q4 2025 revenue of $2.4 million, up 4% year over year and 9% sequentially, as targeted accounts increased their use of the company’s systems. Management framed this as early proof that its focused commercial strategy can generate growth even as the broader business still works through restructuring and portfolio changes.

Surge in U.S. console sales and higher pricing

U.S. console sales jumped 208% in Q4, with eight units sold versus three in the prior-year period, signaling renewed traction for the core platform. The company also lifted circuit average selling prices by 11% year over year, suggesting it is gaining pricing power in key markets and improving the revenue mix per procedure.

Gross margin expansion signals structural improvement

Gross margin in Q4 expanded to 68.2%, up nearly 10 percentage points from 58.4% a year ago, while full-year margin improved to 62%. Management attributed these gains to manufacturing changes and portfolio pruning, arguing that these structural improvements could help offset the drag from slower headline revenue.

Operational and strategic realignment underway

The company completed its manufacturing transition to KDI Precision Manufacturing, aiming to boost reliability and long-term margins while reducing quality issues. It also exited loss-making European territories and narrowed its strategy to the cardiorenal continuum, focusing resources on segments where it sees the strongest clinical and commercial potential.

Pediatrics and heart failure show strong traction

Nuwellis highlighted sharp growth in heart failure and pediatric applications, noting call commentary of more than eightfold year-over-year expansion in these areas. The business also broadened its pediatric intellectual property and secured nondilutive funding from a federal grant to accelerate development of specialized pediatric devices.

Product portfolio expansion through acquisitions

Management discussed recent deals involving Rendiatek and integration work around RoentDeck technologies as it builds a more complete critical care offering. Plans include a midyear relaunch of the Clarity product and adding urine-output and biomarker measurement into ICU workflows, with the goal of deepening utilization within existing hospital accounts.

Expense discipline and balance-sheet actions

For 2025, operating expenses came in at about $16.2 million, modestly below the prior year as management cut discretionary spending and shut down a costly clinical trial. The company also raised roughly $7 million in net proceeds over the year and ended with no debt, positioning itself to extend runway despite ongoing losses.

Full-year revenue decline reflects utilization and international cuts

Despite the stronger fourth quarter, full-year 2025 revenue fell 5% to $8.3 million, reflecting lower consumable usage, softer U.S. console pricing across the year, and reduced international contribution after exiting unprofitable markets. Management framed this pullback as a necessary reset to build a more sustainable, higher-margin base.

Heavy net loss and continued cash burn

Nuwellis posted a net loss attributable to common shareholders of $17.5 million in 2025, including a sizable noncash warrant valuation charge and executive severance. Cash utilization reached about $10.9 million, leaving only around $1.2 million in cash at year-end, underscoring the urgency of turning operational gains into more durable cash flow.

Critical care segment under pressure

Critical care revenue was a weak spot, declining 24% in the quarter and 19% for the full year, partially offsetting progress elsewhere in the portfolio. Management acknowledged this pressure and indicated that upcoming product integrations and workflow tools are intended to stabilize and eventually reaccelerate performance in this segment.

Q4 operating costs edge higher, losses flat

Fourth-quarter operating expenses rose to $4.1 million, about $400,000 higher than the prior-year period, reflecting investments in professional services, recruiting, and development initiatives. Despite this, Q4 operating loss held steady at $2.4 million year over year, as margin improvements and revenue growth helped absorb the higher spend.

Dependence on financing and nonrecurring items

The company’s capital structure remains reliant on external funding, with roughly $7 million raised during 2025 to support operations through the transition phase. Management also pointed to one-time items such as the $6.4 million noncash warrant valuation expense, highlighting how nonoperational factors continue to sway reported bottom-line results.

Program disruptions and quality-driven changes

Management referenced earlier product recall and quality issues that pressured the business and prompted the shift to KDI manufacturing. The decision to terminate the REVERSE-HF clinical trial avoided roughly $3 million in planned spending but also meant stepping back from a potentially valuable longer-term clinical and marketing asset.

Guidance centers on execution, margins, and capital discipline

Looking ahead to 2026, Nuwellis is not leaning on aggressive top-line targets but on improving visibility and consistency in its commercial engine. Priorities include deeper penetration and utilization in active accounts, maintaining elevated gross margins, holding operating expenses in check, carefully deploying capital, and leveraging the KDI transition and new product integrations to convert recent console sales momentum into more predictable growth.

Nuwellis’ earnings call showcased a company mid-turnaround, with solid Q4 growth, better margins, and targeted segments like pediatrics gaining momentum. Yet full-year revenue declines, sustained losses, and thin cash reserves mean investors will be watching closely to see whether 2026 execution can translate strategic progress into sustainable growth and a stronger financial footing.